Related News

No related news articles were found.

venaxis inc (APPY) Related Businessweek News

No Related Businessweek News Found

venaxis inc (APPY) Details

Venaxis, Inc., an in vitro diagnostic company, engages in the development and commercialization of products for unmet diagnostic and therapeutic needs. The company’s research, development, and commercial activities primarily focus on a human acute appendicitis blood-based test. Its lead product candidate includes APPY1, a novel blood-based diagnostic test designed to aid in the evaluation of patients for acute appendicitis. Venaxis, Inc., through its license agreement with Washington University in St. Louis, develops, markets, sells, distributes, imports, and exports luteinizing hormone and/or follicle-stimulating hormone products for bovine, equine, and swine animals. The company was formerly known as AspenBio Pharma, Inc. and changed its name to Venaxis, Inc. in December 2012. Venaxis, Inc. was founded in 2000 and is based in Castle Rock, Colorado.

venaxis inc (APPY) Key Developments

Venaxis Seeks Acquisitions

Jun 26 15

Venaxis, Inc. (NasdaqCM:APPY) is looking for acquisition opportunities. Steve Lundy, President and Chief Executive Officer of Venaxis, said, "we were considering options to possibly acquire or gain access to assets beyond our core focus of appendicitis diagnostic development and commercialization. Over the last few months, we have identified numerous companies with what we believe have attractive assets and opportunities."

Venaxis, Inc. - Shareholder/Analyst Call

Jun 22 15

To provide an update on regulatory and business matters

John H. Landon to Retire as Director of Venaxis, Inc., Effective June 1, 2015

May 12 15

Venaxis, Inc. announced that at the Board meeting held on May 6, 2015, John H. Landon, a director since December 2008, announced his intention to retire from his Board service effective June 1, 2015.

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.